BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.08 USD -1.36% Intraday chart for BioCryst Pharmaceuticals, Inc. -7.47% -15.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Traders Await Inflation Data This Week DJ
BioCryst Launches Hereditary Angioedema Drug in Italy MT
BioCryst Launches Orladeyo (Berotralstat) in Italy CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit MT
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 CI
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) CI
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 CI
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise MT
BioCryst Pharmaceuticals Receives Argentine Regulatory Approval for Orladeyo MT
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina CI
BioCryst Pharmaceuticals Says Hereditary Angioedema Treatment Gets Marketing Authorization in Spain MT
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO CI
BioCryst Says Trial Data Show Treatment With Orladeyo Leads to Reduction of Hereditary Angioedema Attacks MT
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration MT
Transcript : BioCryst Pharmaceuticals, Inc. - Special Call
Transcript : BioCryst Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Chart BioCryst Pharmaceuticals, Inc.
More charts
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.08 USD
Average target price
12.2 USD
Spread / Average Target
+140.16%
Consensus